Biocentury: AVEO’s FDA Woes for Renal Cell Carcinoma Drug stops Astella’s Funding

AVEO Pharmaceuticals’ (AVEO) New Drug Application (NDA) with the FDA for their newly developed once a day oral medication to fight advanced renal cell carcinoma – known as Tivozanib – has hit a snag.Upon review, the FDA’s Oncologic Drugs Advisory Committee voted 13-1 against approval due to safety concerns.

Read more »